A Phase I study of alpelisib in combination with trastuzumab and LJM716 in patients with PIK3CA-mutated HER2-positive metastatic breast cancer

BACKGROUND: Activating mutations in PIK3CA promote resistance to HER2-targeted therapy in breast cancer, however inhibition of PI3K alone leads to escape via feedback upregulation of HER3. Combined inhibition of HER2, HER3 and PI3K overcomes this mechanism preclinically. METHODS: This phase I study...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Cancer Res
Autors principals: Jhaveri, Komal, Drago, Joshua Z., Shah, Payal Deepak, Wang, Rui, Pareja, Fresia, Ratzon, Fanni, Iasonos, Alexia, Patil, Sujata, Rosen, Neal, Fornier, Monica N., Sklarin, Nancy T., Chandarlapaty, Sarat, Modi, Shanu
Format: Artigo
Idioma:Inglês
Publicat: 2021
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8282678/
https://ncbi.nlm.nih.gov/pubmed/33947692
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-21-0047
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars